Corcept Therapeutics (NASDAQ:CORT) Posts Quarterly Earnings Results, Misses Estimates By $0.13 EPS

Corcept Therapeutics (NASDAQ:CORT) released its quarterly earnings data on Tuesday. The biotechnology company reported $0.20 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.13), FiscalAI reports. The firm had revenue of $202.13 million during the quarter, compared to the consensus estimate of $254.94 million. Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.18%. The business’s revenue was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.26 earnings per share.

Here are the key takeaways from Corcept Therapeutics’ conference call:

• Corcept reported 2025 revenue of $761 million (up from $675M) and provided 2026 revenue guidance of $900 million–$1 billion, driven primarily by its Cushing’s syndrome business.
• The FDA issued a complete response letter denying approval of relacorilant for Cushing’s syndrome; the company plans an April meeting with FDA and intends to appeal, resubmit, or possibly run a new study — creating regulatory uncertainty and potential delays.
• The Phase 3 ROSELLA trial in platinum‑resistant ovarian cancer met both primary endpoints, showing a 35% reduction in risk of death (HR 0.65, p=0.0004) and a 4.1‑month median OS benefit; Corcept expects an oncology PDUFA date of July 11 and foresees rapid adoption if approved.
• Demand for Korlym surged in 2025 (37% more tablets; record new prescriptions and prescribers); prior specialty pharmacy capacity issues are being resolved after a vendor transition, and management expects continued commercial growth (targeting at least $2 billion annual Cushing revenue by decade end).
• The pipeline advanced: a Phase 2b MASH study (MONARCH) is fully enrolled with results due by year‑end, and ALS data (DASLES) showed an 84% reduction in risk of death (p=0.0009), prompting a planned pivotal trial after addressing GI tolerability via dose‑titration work.

Corcept Therapeutics Stock Performance

Shares of CORT stock traded down $1.47 during mid-day trading on Thursday, reaching $34.76. The stock had a trading volume of 507,970 shares, compared to its average volume of 2,338,539. The company has a current ratio of 3.14, a quick ratio of 3.07 and a debt-to-equity ratio of 0.01. Corcept Therapeutics has a 1-year low of $28.66 and a 1-year high of $117.33. The firm has a market cap of $3.66 billion, a price-to-earnings ratio of 42.39 and a beta of 0.25. The business’s fifty day moving average is $46.29 and its 200-day moving average is $66.23.

Key Headlines Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Company issued 2026 revenue guidance of $900M–$1.0B and highlighted relacorilant’s nearing oncology approval, which supports upside if the NDA is approved and commercial rollout goes as planned. Read More.
• Neutral Sentiment: HC Wainwright trimmed a long-range FY2030 EPS forecast (from $7.74 to $7.19) but kept a Buy rating and a $67 target, signaling continued analyst faith in the long-term story despite revisions. Read More.
• Negative Sentiment: Q4 results missed expectations — EPS and revenue came in below consensus (reported EPS $0.20 vs. estimates ~ $0.27–$0.33; revenue ~$202M vs. ~$255M consensus). Management’s near-term performance shortfall is a clear driver of the stock weakness. Read More.
• Negative Sentiment: Multiple law firms have filed or are soliciting lead-plaintiff motions in securities class actions covering Oct 31, 2024–Dec 30, 2025; the filings allege failures to disclose FDA concerns about the adequacy of evidence supporting the relacorilant NDA — increasing litigation risk and headline volatility. Read More. Read More.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Corcept Therapeutics in a research report on Monday, December 29th. HC Wainwright decreased their price target on shares of Corcept Therapeutics from $105.00 to $67.00 and set a “buy” rating for the company in a research report on Friday, February 20th. Zacks Research cut shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. Canaccord Genuity Group boosted their price objective on shares of Corcept Therapeutics from $99.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, January 23rd. Finally, UBS Group assumed coverage on shares of Corcept Therapeutics in a research report on Tuesday, December 16th. They set a “neutral” rating and a $95.00 target price for the company. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $77.17.

Insider Transactions at Corcept Therapeutics

In other news, insider Sean Maduck sold 20,000 shares of the company’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $79.52, for a total value of $1,590,400.00. Following the sale, the insider directly owned 7,904 shares of the company’s stock, valued at $628,526.08. This represents a 71.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Joseph Douglas Lyon sold 5,000 shares of the firm’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $79.53, for a total transaction of $397,650.00. Following the transaction, the insider directly owned 10,277 shares of the company’s stock, valued at approximately $817,329.81. This trade represents a 32.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 125,000 shares of company stock worth $8,301,450 in the last ninety days. Corporate insiders own 20.80% of the company’s stock.

Hedge Funds Weigh In On Corcept Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Virtu Financial LLC purchased a new stake in shares of Corcept Therapeutics in the fourth quarter worth about $456,000. Invesco Ltd. boosted its position in Corcept Therapeutics by 11.5% in the 4th quarter. Invesco Ltd. now owns 816,996 shares of the biotechnology company’s stock worth $28,431,000 after purchasing an additional 84,413 shares in the last quarter. FAS Wealth Partners Inc. grew its stake in shares of Corcept Therapeutics by 0.6% during the 4th quarter. FAS Wealth Partners Inc. now owns 310,018 shares of the biotechnology company’s stock worth $10,789,000 after purchasing an additional 1,700 shares during the period. XTX Topco Ltd acquired a new stake in shares of Corcept Therapeutics during the 4th quarter worth approximately $2,803,000. Finally, Tang Capital Management LLC purchased a new position in shares of Corcept Therapeutics during the 4th quarter valued at approximately $5,455,000. Hedge funds and other institutional investors own 93.61% of the company’s stock.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.